Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Melanoma 7Carcinoma, Renal Cell 6Neoplasm Metastasis 4Carcinoma, Transitional Cell 3Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Prostatic Neoplasms 2Penile Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Glioblastoma 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Basal Cell 2Vulvar Neoplasms 1Ureteral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Sjogren's Syndrome 1Seminoma 1Scleroderma, Systemic 1Sarcoma 1Rectal Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 5Specimen Handling 4Nivolumab 3ulixertinib 2dabrafenib 2binimetinib 2Surveys and Questionnaires 2Sunitinib 2Ipilimumab 2Immunoglobulin G 2Disulfides 2Cetuximab 2CTLA-4 Antigen 2Biopsy 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1temsirolimus 1selpercatinib 1sapanisertib 1repotrectinib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1gallium Ga 68 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thyroid Neoplasms × CTLA-4 Antigen × 30 days × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03914300 2026-06-01

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
11 enrolled 11 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡